HLS Therapeutics Inc., a Canadian pharmaceutical company listed on the TSX under the symbol HLS, has entered into a partnership with Bayer to commercialize VERQUVO® in Canada. This agreement will allow HLS to leverage Bayer's expertise and resources to improve access to this innovative treatment for patients suffering from heart failure. The focus of the collaboration aligns with HLS's mission to meet significant unmet medical needs, particularly in the psychiatric and cardiovascular fields.
VERQUVO®, known generically as vericiguat, is designed to treat adults with heart failure and is intended for use in patients who were previously stabilised following hospitalization due to worsening heart failure. The partnership is expected to streamline the distribution and marketing of VERQUVO® in Canada, enhancing its availability to healthcare providers and patients alike.
This announcement was made as part of HLS's ongoing strategy to expand its portfolio of therapies, ensuring that Canadians have access to cutting-edge treatments. HLS continues to seek opportunities to collaborate with other industry leaders to deliver critical healthcare solutions.
Analyzed Canadian Outlets (1)
1 headline